文献速递眼底病与葡萄膜炎

L-苏糖酸通过调控CCL3-CCR5信号通路抑制病理性视网膜新生血管

L-Threonic Acid Inhibits Pathological Retinal Neovascularization by Modulation of CCL3-CCR5 Signaling Pathway.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究基于糖尿病视网膜病变患者血清和玻璃体的代谢组学数据,发现L-苏糖酸(L-ThA)在增殖性糖尿病视网膜病变(PDR)中显著下调。在氧诱导视网膜病变(OIR)小鼠模型中,玻璃体腔注射L-ThA将视网膜新生血管面积从12.34%降至1.67%,其作用机制为抑制视网膜微胶质/巨噬细胞中CCL3的表达和分泌,从而减少其与血管内皮细胞上CCR5受体的相互作用。

要点

  • L-ThA在PDR患者血清和玻璃体中均显著下调,且与疾病进展相关。
  • OIR小鼠中玻璃体腔注射L-ThA使视网膜新生血管面积从12.34%降至1.67%。
  • L-ThA通过抑制微胶质/巨噬细胞CCL3分泌及内皮CCR5相互作用发挥抗血管生成作用。

核心结论

  • L-ThA是PDR中持续下调的代谢物,具有抗血管生成效应,可能成为PDR的生物标志物和治疗靶点。

研究设计与样本

  • 基于糖尿病视网膜病变患者血清和玻璃体的跨组织代谢组学分析,筛选与PDR进展负相关的候选代谢物。
  • 采用氧诱导视网膜病变(OIR)小鼠模型,玻璃体腔注射候选代谢物以验证其对视网膜新生血管的抑制作用。
  • 通过转录组测序、蛋白质印迹、共培养实验等分子技术阐明下游信号机制。

主要发现

  • PDR患者血清和玻璃体差异代谢物交集分析显示L-ThA在两种生物体液中均显著下调。
  • L-ThA水平降低与疾病进展相关。
  • OIR小鼠中玻璃体腔注射L-ThA使视网膜新生血管面积从12.34%降至1.67%,抗血管生成效果接近抗VEGF疗法。
  • L-ThA通过抑制视网膜微胶质/巨噬细胞中CCL3的表达和分泌,减少其与血管内皮细胞上CCR5受体的相互作用,从而抑制视网膜新生血管。

临床怎么用

  • L-ThA可能作为PDR的潜在生物标志物,用于疾病进展风险评估。
  • L-ThA及CCL3-CCR5信号通路可能成为PDR抗血管生成治疗的新靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Based on the integrated metabolomics data of serum and vitreous humor from diabetic retinopathy, this study aimed to elucidate the inhibitory effects and underlying mechanisms of L-threonic acid (L-ThA) on retinal neovascularization. METHODS: Cross-tissue metabolomic analysis identified consistently altered metabolites in both biofluids. Candidates negatively associated with proliferative diabetic retinopathy (PDR) progression were then selected through mass spectrometry analysis and disease risk assessment. To validate the inhibitory effects of these metabolites on retinal neovascularization, an oxygen-induced retinopathy (OIR) mouse model was used, and compounds were delivered intravitreally. The downstream signaling mechanisms of these metabolites were further elucidated using transcriptome sequencing, western blotting, co-culture assays, and other complementary molecular techniques. RESULTS: Intersection analysis of differential metabolites in serum and vitreous humor from patients with PDR revealed that L-ThA was significantly downregulated in both biofluids. The reduction in L-ThA levels was associated with disease progression. In a mouse model of OIR, intravitreal injection of L-ThA markedly reduced the retinal neovascular area from 12.34% to 1.67%, demonstrating potent anti-angiogenic effects approaching the efficacy of those anti-vascular endothelial growth factor therapies. Transcriptomic and molecular analyses further elucidated that L-ThA suppresses retinal neovascularization by inhibiting the expression and secretion of C-C motif chemokine ligand 3 (CCL3) in retinal microglia/macrophages, thereby reducing its interaction with the CCR5 receptor on vascular endothelial cells. CONCLUSIONS: Cross-tissue metabolomics revealed L-ThA as a metabolite consistently downregulated in PDR; functional studies suggest it possesses anti-angiogenic effects by modulation of CCL3-CCR5 signaling, representing a potential biomarker and therapeutic target for PDR.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Sun H, Zhou L, Luo T, et al. L-Threonic Acid Inhibits Pathological Retinal Neovascularization by Modulation of CCL3-CCR5 Signaling Pathway. Invest Ophthalmol Vis Sci. 2026. PMID: 42808830. doi:10.1167/iovs.67.11.51

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。